


Summary

Name	ANGPTL3/Angiopoietin-related Protein 3
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Angiopoietin-related Protein 3 is produced by our Mammalian expression system and the target gene encoding Ser17-Pro220 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession #	Q9Y5C1
Host	Human Cells
Species	Human
Predicted Molecular Mass	50.7 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, 5% Trehalose, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Human ANGPTL3 (C-Fc)
Catalog #: PHH2242



Alternative Names

Angiopoietin-related protein 3; ANGPTL3; Angiopoietin-5; ANG-5; Angiopoietin-like protein 3; ANGPT5

Background

Angiopoietin-like 3 (ANGPTL3) is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C-terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Full length ANGPTL3 circulates in the plasma as do the proteolytically separated N- and C-terminal segments containing the coiled coil domain and fibrinogen-like domains, respectively. ANGPTL3 directly inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), enzymes responsible for hydrolyzing circulating triglycerides and HDL phospholipids. ANGPTL3 promotes an increase in circulating triglyceride levels without altering VLDL or HDL secretion or uptake. ANGPTL3 expression in vivo is up-regulated by LXR agonists and down-regulated by insulin, leptin, and agonists of TR β or PPAR β .

Note

For Research Use Only , Not for Diagnostic Use.